CEL-SCI Advances in Cancer Treatment with FDA Approval for Confirmatory Multikine Study
In a landmark decision, the U.S. Food and Drug Administration (FDA) has green-lighted CEL-SCI Corporation (NYSE American: CVM)…
BIOQUAL Reports Positive Q3 Growth Following Year of Steady Performance
BIOQUAL (OTC Pink: BIOQ) is a company noted for its contributions to health science research. The company’s most…
Petros Pharmaceuticals Advances STENDRA OTC Bid with Positive FDA Feedback
Petros Pharmaceuticals, Inc. has taken a significant step toward making its erectile dysfunction drug, STENDRA, available over-the-counter (OTC),…
RAPT Therapeutics Announces Promising Phase 2 Trial Results for Tivumecirnon
RAPT Therapeutics, a clinical-stage biopharmaceutical company, has announced promising results from its Phase 2 clinical trial of Tivumecirnon…
Cigna Humana Merger Plans Come To Halt
The healthcare insurance landscape was on the brink of a major shift with the potential “Cigna Humana merger…
TaiMed Biologics Unveils Promising Results for Innovative Long-Acting HIV Treatment
TaiMed Biologics, a pioneering biotechnology firm, has marked a significant milestone in the fight against HIV. The company…
Botanical Solution, Inc. Amplifies Vaccine Adjuvant Production with a Fresh $7 Million Investment
Botanical Solution Inc. (BSI), a global trailblazer in the production of sustainable Advanced Botanical Materials, announces the addition…
Immunis, Inc. Recognized as a Finalist in the Octane High Tech Awards for Best Emerging Technology Company
Immunis, Inc., a pioneering entity in the biotechnology landscape, has achieved a significant milestone by being named a…
CEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022
CEL-SCI recently presented its Phase 3 data at ESMO 2022, which revealed that Neoadjuvant Multikine achieved groundbreaking tumor…
SyneuRx CEO Dr. Emil Tsai Exclusive Interview with Insights & Projections
Our BioTech Health X CEO Series continues with an exclusive interview with Dr. Emil Tsai of SyneuRx. Today…
Mayo Clinic, Hibiscus BioVentures, and Innoforce Announce Mayflower Cell and Gene Therapy Accelerator
Mayo Clinic, Hibiscus BioVentures (Hibiscus), and Innoforce have announced the formation of Mayflower BioVentures, a cell and gene…
Krystal Biotech Announces FDA IND Acceptance for KB407 Cystic Fibrosis Clinical Trial
Leader in redosable gene therapy Krystal Biotech, Inc. (NASDAQ: KRYS) announced today the United States Food and Drug…
ImmunityBio Announces FDA Acceptance of BLA for N-803 Anktiva Bladder Cancer Drug
In breaking news, clinical-stage biotechnology company ImmunityBio, Inc. (NASDAQ: IBRX) has announced acceptance by the FDA review of…
Brickell Biotech Regains Nasdaq Compliance Meeting Minimum Bid Price Requirement
Clinical-stage pharmaceutical company Brickell Biotech, Inc. (Nasdaq: BBI) announced that the company has received formal notice from The…
Merck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial
Today Merck & Co. (NYSE: MRK) announced that Keytruda has failed the Phase 3 clinical trial KEYNOTE-412 evaluating…
What is Biotechnology: Types, Examples and Applications
Understanding biotechnology Biotech involves studying organism functions at the molecular level and is often combined with many different…
Ocugen Announces FDA Clinical Hold Removal for Phase 2/3 COVAXIN (BBV152) Clinical Trial
Biotechnology company Ocugen, Inc. (NASDAQ: OCGN) announced today that the U.S. Food and Drug Administration (FDA) has removed…
BenchSci Expands Advisory Board with New Pharma R&D Leaders
BenchSci has welcomed three new members to its advisory board from the pharmacology sector. Steve Hitchcock of Takeda…